ADAPY:OTCMKTS
Adaptimmune Therapeutics PLC - ADR
US$0.0036
arrow_downward
-64.00%(-0.0064) 1D
වෙසක් 1, 16.00.00 ග්රිමවේ-4 · USD
search
සියලු සංකේත
1D
5D
1M
6M
YTD
1Y
5Y
උපරි
| සංකේතය | මිල | වෙනස් කිරීම | % වෙනස |
|---|
insights_autoADAPY සඳහා ඉහළම ඇතුළාන්තයන් උත්පාදනය කරමින්...
විවෘත කරන්න
US$0.00
ඉහළ
US$0.02
පහළ
US$0.00
වෙ.පො ප්රාග්ධනය
ද954.19
දළ පරිමාව
ද281.50
හඬ පරිමාණය
ද64.61
සති-52 ඉහළ
US$0.36
සති-52 පහළ
US$0.00
EPS
-US$0.66
බීටා
2.42
ගෙවිය යුතු කොටස්
මි265.05
සේවකයින් ගණන
506
පුවත් සහ කථා
වෙබය හරහා මූලාශ්ර වෙතින්
Yahoo Finance
·
මිනිත්තු 39කට පෙර
Goldman Sachs says the S&P 500's run past 7,100 is 'froth' — a previous time Wall Street said that, a crash followed
Simply Wall Street
·
පැය 1කට පෙර
Wingstop Weighs AI Loyalty Push India Entry And Smart Kitchen Gains
MarketBeat
·
පැය 1කට පෙර
Perella Weinberg Partners (NASDAQ:PWP) Announces Quarterly Earnings Results
Investor's Business Daily
·
පැය 2කට පෙර
Dow Jones Futures: Stock Market Hits High After Bullish Pause; Apple, Broadcom In Buy Zones
පැතිකඩ
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
Adaptimmune Therapeutics PLC - ADR ගැන
AI අන්තර්ගතයේ වැරදි ඇතුළත් විය හැක. තව දැන ගන්න